MétaCan
Menu
Back to cohort
Record W4397025153 · doi:10.1681/asn.20203110s1491b

Canadian Real-World Assessment of Tolvaptan in ADPKD: C-MAJOR Study and Safety Monitoring and Distribution Program

2020· article· en· W4397025153 on OpenAlexaffabout
Philip A. McFarlane, Patrick S. Parfrey, Daniel G. Bichet, L. E. Bergeron, Annick Laplante

Bibliographic record

VenueJournal of the American Society of Nephrology · 2020
Typearticle
Languageen
FieldMedicine
TopicElectrolyte and hormonal disorders
Canadian institutionsMemorial University of NewfoundlandUniversité de MontréalSt. Michael's Hospital
Fundersnot available
KeywordsTolvaptanMedicineDistribution (mathematics)Internal medicineIntensive care medicineMathematicsHyponatremia

Abstract

fetched live from OpenAlex

Background: Tolvaptan is the only approved treatment in Canada for slowing renal function decline and kidney enlargement in ADPKD patients. As per Health Canada requirement, a patient registry evaluating long-term clinical outcomes (C-MAJOR study) and a hepatic safety monitoring and distribution program (HSMDP) to mitigate risk of liver injury were implemented and have been ongoing for 5 years. The aim of this interim analysis is to describe baseline characteristics of patients at initiation of tolvaptan through the C-MAJOR study and to report on treatment persistence and liver transaminases elevation rate through the HSMDP. Methods: C-MAJOR is a non-interventional, multi-centre study of ADPKD patients treated with tolvaptan. HSMDP ensures tolvaptan is dispensed under controlled liver function monitoring. Results: As of April 2020, 398 patients, 51% female, were enrolled in C-MAJOR. At baseline, mean (SD) age was 45.1 (11.5) years, BP was 129.4 (13.4)/83.1 (10.0) mmHg and eGFR was 63.6 (27.8) mL/min/1.73 m2. Total kidney volume was 1949 (1562) mL, 80.7% of patients had a family history of ADPKD and 39.4% had a family history of early end-stage renal disease. As per Mayo classification, 90.2% were at high risk of disease progression (1C-D-E). The most common ADPKD clinical manifestations were hypertension (83.2%), hepatic cysts (69.6%) and kidney pain (24.1%). Over a mean (SD) follow-up of 2.0 (1.0) years, adverse events were reported in 82.7% of patients, most common being polyuria (19.6%), fatigue (18.6%), and nocturia (15.1%). Over a mean (SD) follow-up of 23.0 (17.6) months in the HSMDP, 2.4% (39) of the 1,600 patients who received at least one shipment of tolvaptan reported an elevation of transaminases >3x ULN. There were 0.3% (5) of patients meeting the guidelines for permanent discontinuation. No cases of drug-induced liver injury were reported. Treatment discontinuation rates at 12, 24 and 36 months were 14%, 21% and 26%, respectively. Conclusions: This analysis provides Canadian real-world evidence of high-risk disease progression at tolvaptan initiation, 3-y persistence data similar to phase III study and the HSMDP showing tolvaptan was permanently discontinued in 0.3% of patients because of hepatic effects. Funding: Commercial Support - Otsuka Canada Pharmaceutical Inc.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.069
Threshold uncertainty score0.159

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.007
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.004
Science and technology studies0.0020.001
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.324
Teacher spread0.308 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueJournal of the American Society of NephrologySame topicElectrolyte and hormonal disordersFrench-language works237,207